BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 9:32:33 AM | Browse: 762 | Download: 1994
 |
Received |
|
2021-03-23 08:25 |
|
Peer-Review Started |
|
2021-03-23 08:28 |
|
First Decision by Editorial Office Director |
|
2021-07-27 06:16 |
|
Return for Revision |
|
2021-07-27 06:16 |
|
Revised |
|
2021-08-09 19:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-10-18 06:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-10-18 09:25 |
|
Articles in Press |
|
2021-10-18 09:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-17 06:01 |
|
Publish the Manuscript Online |
|
2021-11-19 09:32 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jenny Isaksson, Henrik Green, Dimitrios Papantoniou, Linn Pettersson, Mats Anden, Johan Rosell, Elisabeth Åvall-Lundqvist and Nils Oskar Elander |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nils Oskar Elander, MD, PhD, Doctor, Doctor, Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping University Hospital, Linköping 58185, Sweden. nils.elander@liu.se |
| Key Words |
Prostate cancer; Chemotherapy; Docetaxel; Castration sensitive; Metastatic; Real world |
| Core Tip |
Two recent trials reported impressive outcomes when upfront docetaxel is added to androgen deprivation therapy in metastatic castration-sensitive prostate cancer (mCSPC). This study presents the outcome and safety of this treatment strategy in a real-world context of all eligible patients in the southeast region of Sweden. While the treatment is toxic in terms of febrile neutropenia and unplanned hospitalizations, the outcome and long-term prognosis appear similar in real life and randomized controlled trial contexts. Further implementation of upfront docetaxel in mCSPC in routine care is encouraged. |
| Publish Date |
2021-11-19 09:32 |
| Citation |
Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Åvall-Lundqvist E, Elander NO. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol 2021; 12(11): 1009-1022 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i11/1009.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i11.1009 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
